The American Association for Cancer Research (AACR) recently announced that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Dr. Von Hoff is being recognized for his groundbreaking accomplishments as an educator; his scientific innovation, which has accelerated advances in cancer science and medicine; and his contributions to the education and training of thousands of clinical cancer investigators.
Dr. Von Hoff’s personal tutelage and professional guidance of young clinical fellows and junior clinical faculty for more than 2 decades have contributed not only to their educational background and training, but also to their ability to apply the principles learned to improve the care of countless patients with cancer around the world. Future awards will be presented to individuals who have made significant contributions to the education and training of cancer scientists and physicians at any career level and in any area of cancer research.
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR
Scientific Leadership and Mentorship
Dr. Von Hoff is Distinguished Professor at the Translational Genomics Research Institute in Phoenix; Distinguished Professor, Department of Medical Oncology and Therapeutics Research, at City of Hope in Duarte, California; Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute; Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Family Cancer Institute; Chief Scientific Officer for US Oncology Research; and Professor of Medicine at the University of Arizona and the Mayo Clinic in Scottsdale, Arizona.
An internationally renowned cancer researcher, Dr. Von Hoff has contributed to the discovery and development of many approved anticancer therapeutics used routinely for numerous types of cancer. They include dexrazoxane, docetaxel, fludarabine, gemcitabine, irinotecan, mitoxantrone, nab-paclitaxel, paclitaxel, topotecan, vismodegib, pexidartinib, and nanoliposomal irinotecan. Notably, his work involving gemcitabine and nab-paclitaxel combination therapy was one of the first to demonstrate improved response rates, progression-free survival, and overall survival in patients with metastatic pancreatic cancer.
In addition, Dr. Von Hoff has long been a champion and mentor of early-career and early-stage investigators and is dedicated to supporting the professional development of the cancer research workforce. He is revered for conceptualizing the AACR/ASCO Methods in Clinical Cancer Research Workshop and for establishing and guiding the development of the course. Since its inception in 1996, the course has become the premier workshop dedicated to educating clinical fellows and junior faculty clinical researchers in oncology specialties in the principles of effective clinical trial designs and therapeutic interventions for cancer.